Related Experiment Video

Updated: Jul 10, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Tyrosine kinase inhibitors in pediatric malignancies

Jeffrey M Skolnik1, Peter C Adamson

  • 1Division of Clinical Pharmacology and Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA. skolnik@email.chop.edu

Cancer Investigation
|October 24, 2007
PubMed

Insights

Tyrosine kinase inhibitors offer targeted cancer therapy. While approved for adult cancers, only imatinib mesylate is currently approved for pediatric cancers, with ongoing research into other inhibitors for childhood cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Tyrosine kinase inhibitors (TKIs) represent a significant advancement in targeted cancer therapy for adults.
  • The discovery of imatinib mesylate marked a new era in treating cancers with molecularly targeted agents.
  • Despite their success in adult oncology, the application of TKIs in pediatric cancer treatment remains limited.

Purpose of the Study:

  • To review the mechanisms of tyrosine kinase inhibition.
  • To explore the potential role of tyrosine kinase pathways in pediatric cancers.
  • To summarize the current status of clinical investigations of TKIs in childhood cancer.

Main Methods:

  • Literature review of tyrosine kinase inhibitors in cancer therapy.
  • Analysis of the role of tyrosine kinase pathways in pediatric malignancies.
  • Summary of ongoing and completed pediatric clinical trials involving TKIs.

Main Results:

  • Tyrosine kinase inhibitors function by blocking specific signaling pathways crucial for cancer cell growth and survival.
  • Several tyrosine kinase pathways are implicated in the development and progression of various childhood cancers.
  • While imatinib mesylate is approved for specific pediatric cancers, a broader range of TKIs are under investigation for childhood malignancies.

Conclusions:

  • Tyrosine kinase inhibitors hold significant promise for targeted treatment of pediatric cancers.
  • Further clinical investigation is essential to expand the use of TKIs in treating childhood cancers.
  • Understanding the specific tyrosine kinase dependencies in pediatric tumors will guide future therapeutic strategies.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...